Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

Table 1

Patient demographics and clinical profile at the time of starting anti-PD-1 therapy.

Pt. No.	Age (years)	Gender	Mutational status	Brain metastasis	Liver metastasis	Prior adjuvant therapy	Prior therapy for metastatic disease	Prior immune-related adverse event	Radiation therapy within prior 3 months	Prior relevant history or autoimmune disease
1	63	Male	BRAF V600E	Yes	No	Interferon	Ipilimumab, stereotactic radiosurgery	Colitis	Yes	None
2	61	Female	BRAF Negative	No	No	Radiation	Ipilimumab	Colitis, rash	No	Lichen planopilaris
3	72	Female	BRAF Negative	No	No	GM-CSF	Ipilimumab	Colitis	No	None
4	81	Male	BRAF V600K, GNAQ, RAC1, POLD1, TERT	Yes	No	No	Radiation, craniotomy and tumor resection, stereotactic radiosurgery	NA	Yes	Thymoma
5	64	Male	BRAF V600E	No	No	Radiation	Ipilimumab with talimogene laherparepvec	None	No	None
6	59	Female	NRAS	Yes	No	Interferon	Ipilimumab, craniotomy and tumor resection, radiation	None	Yes	None
7	66	Female	BRAF V600E	No	No	No	NA	NA	No	None
8	35	Male	BRAF V600E, PTEN, MET	No	No	Interferon	Ipilimumab with interleukin-2, ipilimumab	Diarrhea, nausea, vomiting, hyperbilirubinemia, acute kidney injury, oliguria, tachycardia	No	None
9	61	Male	TP53	No	No	No	NA	NA	No	None
10	77	Male	KIT p.W557G	Yes	No	Radiation	Stereotactic radiosurgery	NA	Yes	None
11	65	Male	NRAS, TP53, KIT, SF3B1, CDK2NA	No	No	No	NA	NA	No	None
12	67	Female	Not done	No	No	No	NA	NA	No	None
13	78	Male	BRAF p.L597S	No	No	No	Carboplatin with paclitaxel	NA	No	No
14	64	Male	BRAF V600K	No	No	Radiation, ipilimumab	NA	Rash	No	No
15	47	Female	BRAF V600E	No	No	Interferon	Vemurafenib with high dose interleukin-2, vemurafenib with decitabine, craniotomy, stereotactic radiosurgery	Rash, diarrhea	Yes	No
16	75	Male	BRAF negative	No	Yes	No	NA	NA	No	Myasthenia gravis